Tau function is regulated by phosphorylation, and abnormal tau phosphorylation in neurons is one of the key processes associated with development of Alzheimer's disease and other tauopathies. In this study we provide evidence that phospholipid transfer protein (PLTP), one of the main lipid transfer proteins in the brain, significantly reduces levels of phosphorylated tau and increases levels of the inactive form of glycogen synthase kinase-3b (GSK3b) in HCN2 cells. Furthermore, inhibition of phosphatidylinositol-3 kinase (PI3K) reversed the PLTP-induced increase in levels of GSK3b phosphorylated at serine 9 (pGSK3b Ser9 ) and partially reversed the PLTP-induced reduction in tau phosphorylation. We provide evidence that the PLTP-induced changes are not due to activation of Disabled-1 (Dab1), insofar as PLTP reduced levels of total and phosphorylated Dab1 in HCN2 cells. We have also shown that inhibition of tyrosine kinase activity of insulin receptor (IR) and/or insulin-like growth factor 1 (IGF1) receptor (IGFR) reverses the PLTP-induced increase in levels of phosphorylated Akt (pAkt Thr308 and pAkt Ser473 ), suggesting that PLTP-mediated activation of the PI3K/Akt pathway is dependent on IR/IGFR receptor tyrosine kinase activity. Our study suggests that PLTP may be an important modulator of signal transduction pathways in human neurons. V V C 2009 Wiley-Liss, Inc.
Phospholipid transfer protein (PLTP) is a versatile, nearly ubiquitously expressed protein, involved in transfer of cholesterol and phospholipids, lipoprotein metabolism, inflammatory processes, apoptosis, and transfer of vitamin E among lipoproteins and between lipoproteins and cells (Hailman et al., 1996; Wolfbauer et al., 1999; Barlage et al., 2001; Desrumaux et al., 2005; Wehinger et al., 2007) . Expression of PLTP in the brain likely plays a significant role in the brain lipid and lipoprotein metabolism (Vuletic et al., 2003) . However, most studies of PLTP thus far have focused on PLTP functions in extracellular lipoprotein metabolism.
Previous studies have shown that PLTP binds and stabilizes ATP-binding cassette A1 (ABCA1; Oram et al., 2003) , indicating that PLTP is capable of binding cell surface receptors. We have recently shown that PLTP is localized in the nucleus, that its nuclear export is chromosome region maintenance-1 (CRM1) dependent, that secreted PLTP can reenter cells and be translocated to the nucleus, and that intranuclear PLTP is active in phospholipid transfer (Vuletic et al., 2009) . Thus PLTP could be involved in regulation of intracellular pathways and processes both by binding of extracellular PLTP to the receptors on the cell surface and by internalization at the plasma membrane either by insertion of the putative transmembrane domain or by whole protein uptake. Alternatively, PLTP synthesized by cells could have distinct intracellular functions. These putative PLTP functions have yet to be studied.
PLTP levels in the central nervous system are altered in neurodegenerative and inflammatory brain disorders, including Alzheimer's disease (AD). Patients with AD have significantly higher levels of PLTP in brain tissue and significantly lower PLTP-mediated phospholipid transfer activity in cerebrospinal fluid than neurologically healthy controls, suggestive of sequestration of PLTP in brain tissue of patients with AD (Vuletic et al., 2003 (Vuletic et al., , 2005 . Pathophysiological consequences of these observed alterations are currently unknown.
The hyperphosphorylation of tau and consequent development of neurofibrillary tangles (NFTs) in the affected neurons represent one of the hallmarks of histologically verified changes in the brain tissue of patients with AD, originally discovered by Alois Alzheimer in 1907 (for review see Iqbal and Grundke-Iqbal, 2006) . Physiological regulation of tau phosphorylation is an important mechanism that ensures undisturbed intracellular transfer through the microtubule system, which is essential for regulation of synaptic functions in neurons (Mandelkow et al., 2003) . Understanding the pathways that are involved in regulation of tightly controlled tau phosphorylation is relevant for our understanding of pathophysiological processes that lead to tau hyperphosphorylation, disintegration of the tubular system, and formation of neurofibrillary tangles in neurons of patients who suffer from AD and other tau-related neurodegenerative diseases. For example, cerebrospinal fluid levels of tau phosphorylated at threonine 231 highly positively correlate with cognitive decline both in people with mild cognitive impairment and in those with AD (Buerger et al., 2002; Gauthier et al., 2006) . These findings strongly suggest that regulation of tau phosphorylation is a critical process in maintenance of normal cognitive functions in humans. In this in vitro study, we tested the hypothesis that PLTP is directly involved in modulation of tau phosphorylation in neuronal cells.
MATERIALS AND METHODS Materials
Cell culture media were obtained from Lonza (Walkersville, MD). Fetal calf serum with low endotoxin levels was obtained from HyClone (Logan, UT). Affinity-purified antibodies against human total Dab1 (catalog No. 3328) Human recombinant PLTP was expressed in baby hamster kidney cells (BHK), isolated, prepared, and evaluated for activity and purity as previously reported (Wolfbauer et al., 1999) .
Cell Culture
Human neuronal cells (HCN2; ATCC CRL-10742) were plated in six-well plates and grown in DMEM supplemented with 12% fetal calf serum at 378C, 5% CO 2 until 80% confluent. Human neuroblastoma cells, SK-N-SH, were used for gene expression analyses and were grown under identical conditions in DMEM supplemented with 4% fetal calf serum. For most experimental purposes, cells were incubated under serum-free conditions, although some experiments were conducted with serum supplementation to exclude the possibility that our findings were due to serum starvation. Viability of cells was evaluated by using trypan blue (Sigma-Aldrich). Briefly, HCN2 cells were grown in serum-free media for 48 hr without or with rPLTP (2, 5, and 10 lg/ml). After incubation, cells were washed, trypsinized, and stained with trypan blue for 3 min; number of total and positively stained cells was established by counting in five separate fields for each experimental condition. Under all experimental conditions, cell viability was above 90%. After incubation, cells were extensively washed to remove dead cells and cell debris and then scraped.
Electrophoresis and Western Blot Analyses
Proteins were isolated by using PhosphoSafe protein isolation solution (EMD Chemicals), which preserves phosphorylated sites in the presence of protease inhibitors (Halt protease inhibitor cocktail; Invitrogen), according to the manufacturer's instructions. Cell proteins were subjected to denaturing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis. Samples were loaded on 4-12% gel (Bio-Rad Bis-Tris Criterion XT) for SDS-PAGE and, after electrophoresis, transferred to nitrocellulose membrane with Bio-Rad semi-dry transfer. Blots were incubated overnight with primary antibodies at 48C with agitation in PhosphoBlocker, a specialized blocker that preserves availability of phosphorylated sites for antibody binding (the same blocker was used in all incubation steps). Loading control was evaluated with b-actin. The blots were incubated with the appropriate TrueBlot secondary antibody for 2 hr at room temperature. The membranes were developed with West Femto SuperSignal chemiluminescent kit, scanned with a Kodak CF400 imaging system, and evaluated by densitometry scanning.
PI3K Inhibition
Cells were grown in serum-free media for 48 hr, in the presence or absence of the PI3K inhibitor LY294002 (50 lM). After incubation, cells were washed, and cell protein was isolated with PhosphoSafe with protease inhibitor cocktail. Cell proteins were separated by SDS-PAGE, and levels of phosphorylated GSK3b and tau were established by Western blotting.
Inhibition of Insulin Receptor Tyrosine Kinase Activity
HCN2 cells were incubated with HNMPA(AM) 3 , an inhibitor of the insulin receptor (IR) and insulin-like growth factor 1 (IGF1) receptor (IGFR) tyrosine kinase activity (Saperstein et al., 1989) . The inhibitor or vehicle (DMSO) was added to serum-free media 2 hr before addition of rPLTP at concentrations previously shown to inhibit IR (50 lM) and IGFR (100 lM; Diaz et al., 2007) and incubated with rPLTP (5 lg/ml) for 10 and 30 min. Cells were then washed and scraped. Isolated proteins were evaluated for total and phosphorylated Akt/PKB by SDS-PAGE/Western blot.
RNA Isolation
RNA was isolated by using a Qiagen RNEasy kit, according to the manufacturer's instructions. To remove trace genomic DNA, samples were treated with DNase and a DNA-Shredder kit (Qiagen). After assessment of 260/280 nm ratio by spectrometry, RNA samples were stored at -708C until use. Total RNA was quantified on the Mx4000 Multiplex QPCR System (Stratagene, La Jolla, CA) using the RiboGreen RNA Quantitation kit (Molecular Probes, Eugene, OR).
Quantitative PCR
Quantitative PCR was performed on an Mx4000 Multiplex QPCR System with samples loaded in triplicate using 40 ng of total RNA. Quantitative PCR was run in a 10-ll reaction with SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA; 5 ll 23 Master Mix, 400 nM each primer, 0.5 units of StrataScript RT, 0.5 U RNase Block) with PCR cycling conditions of 488C for 30 min, 958C for 10 min, and 40 cycles at 958C for 15 sec, 608C for 1 min. After each assay, a dissociation curve was run to confirm specificity of all PCR amplicons. Resulting C t values were converted to nanograms, normalized to total RNA and 18S, and expressed as a ratio of gene expression and total RNA/18S. Pooled sample total RNA was used for standard curves in 1:2 serial dilutions. Primers were from Operon (Huntsville, AL) and were designed in Applied Biosystems Primer Express 2.0 software. Primers used in the study are listed in Table I .
Statistical Analyses
Statistical analyses were performed with Statistica for Windows (StatSoft Inc., Tulsa, OK). Differences were evaluated by Mann-Whitney U-test, Wilcoxon matched-pairs test, and t-test, and P < 0.05 was considered statistically significant.
RESULTS

PLTP Reduces Tau Phosphorylation at Threonine 231 and Serine 199/202
To test whether PLTP affects phosphorylation of tau in neuronal cells, we evaluated the levels of tau phosphorylated at threonine 231, pTau Thr231 , in HCN2 cells incubated with human rPLTP. pTau Thr231 is a known marker for AD (Buerger et al., 2003 (Buerger et al., , 2006 , which correlates with the neurofibrillary tangle burden in the brain of AD patients (Buerger et al., 2006) . Tau phosphorylated at threonine 231 is dependent on activity of GSK3b following priming by Cdk5 (Sengupta et al., 1997; Wang et al., 1998; Platner et al., 2006) . PLTP significantly reduced levels of pTau Thr231 (by approximately 55%, 65%, and 80% at 2, 5, and 10 lg/ml rPLTP, respectively; Fig. 1B,C) , without reduction in levels of total tau (Fig. 1A) . This effect was observable after 6 hr and developed further after 24 and 48 hr (Fig. 1D) . PLTP-induced reduction in pTau Thr231 was not affected by the presence or absence of serum (Fig. 1E) . Similar, but attenuated results were obtained for tau phosphorylated at serine 199 and 202, residues also phosphorylated by GSK3b, with PLTP reducing pTau Ser199,202 by 20% (data not shown). For comparison, we tested the PLTP effect on levels of pTau Ser356 , showing that PLTP reduces phosphorylation of tau at serine 356 as well, but not to the same extent (Fig. 1F,G) . To establish whether PLTP affects expression of tau, human neuroblastoma cells, SK-N-SH, were incubated with PLTP, and isolated mRNA levels were assessed by RT-PCR. Under the experimental conditions employed, PLTP had no effect on tau mRNA levels in SK-N-SH cells (data not shown). These data suggest that PLTP reduces GSK3b-dependent phosphorylation of tau in HCN2 cells in vitro, without affecting levels of total tau. TCTGGTCAAGGCTTTGGGAA  113  GSK3b  NM002093  hGSK3B-1526F  TCCACCTGAACAGTCCCGA  81  hGSK3B-1606R  CGTGACCAGTGTTGCTGAGTG  81  DAB1  NM021080  hDAB1-798F  TACAAAGCCAAATTGATCGGG  87  hDAB1-884R GCCCTTGAGTTTCATCATGGA 87 *h, human; F, forward; R, reverse; DAB1, Disabled 1; GSK3b, glycogen synthase kinase 3b; MAPT, microtubule-associated protein tau. Fig. 1 . PLTP reduces levels of tau phosphorylated at threonine 231 in HCN2 cells. Cells were incubated without or with (2, 5, or 10 lg/ml) human rPLTP, and cell proteins (30 lg) were resolved using SDS-PAGE. A: Total tau in cells incubated for 48 hr in serum-free media. B: Levels of pTau Thr231 in cells incubated for 48 hr in serum-free media. C: PLTP effect on levels of pTau Thr231 ; results of three separate experiments, each performed in triplicate (n 5 9; *P < 0.05 compared with control cells). D: Time-dependent changes in pTau Thr231 levels in cells incubated without or with (5 lg/ml) human rPLTP for 6, 24, and 48 hr. E: pTau Thr231 levels in cells incubated without or with (5 lg/ml) rPLTP for 48 hr under serum-free conditions and in the presence of serum. F: Timedependent changes of pTau Ser356 in cells incubated without or with rPLTP (5 lg/ml) for 6, 24, and 48 hr. G: Dose-dependent changes of pTau Ser356 in cells incubated for 48 hr with 2, 5, or 10 lg/ml rPLTP. Antibodies against tau (total and phosphorylated) were used at 1:800; anti-actin antibody was used at 1:12,000.
PLTP Increases Levels of Inactive Form of GSK3b (pGSK3b Ser9 ) in Human Neuronal Cells
Previously published studies have shown that phosphorylation of tau at threonine 231 is at least partially regulated by GSK3b (Sengupta et al., 1997; Platner et al., 2006; Wang et al., 2007 ). Therefore, we tested the effects of human PLTP on levels of GSK3b phosphorylated at serine 9, pGSK3b Ser9 , the inactive form of GSK3b, in HCN2 cells. PLTP induced a significant increase in pGSK3b Ser9 (by approximately 70-85%; Fig.  2B,C) , without an increase in either GSK3b mRNA levels (data not shown) or levels of total GSK3b in neuronal cells (Fig. 2A) . The PLTP-mediated change in pGSK3b Ser9 levels was observed after 6 hr of incubation (Fig. 2D ) and was not affected by addition or removal of serum (Fig. 2E) . These data suggest that PLTP increases the amount of the inactive form of GSK3b in HCN2 cells.
Phosphorylation of GSK3b at serine 9 is regulated by the PI3K pathway (Krasilnikov, 2000) . Inhibition of PI3K by LY294002 reversed the PLTP-induced increase of pGSK3b Ser9 and thereby partially reversed the PLTPinduced reduction in tau phosphorylation (Fig. 3) .
PLTP-Mediated Reduction in pGSK3b Ser9 Is Not Dependent on the Dab1-Dependent Pathway
Activation of the PI3K pathway is elicited through a ligand binding to receptors on the cell membrane, and two well-defined pathways involved in the PI3K-mediated regulation of GSK3b have been reported. One involves binding of apoE or Reelin to the apoE receptors APOER2 or VLDLR and consequent tyrosine phosphorylation of Disabled-1 (Dab1) by an Src-homology kinase, Fyn (Wang et al., 1998; Hiesberger et al., 1999; Howell et al., 1999a,b; Ohkubo et al., 2003; Brich Fig. 2 . PLTP increases levels of glycogen synthase kinase (GSK3b) phosphorylated at serine 9 in HCN2 cells. Cells were incubated without or with (2, 5, or 10 lg/ml) human rPLTP, and cell proteins (30 lg) were resolved by using SDS-PAGE. A: Total GSK3b in cells incubated for 48 hr in serum-free media. B: Levels of pGSK3b Ser9 in cells incubated for 48 hr in serum-free media. C: PLTP effect on levels of pGSK3b Ser9 ; results of three separate experiments, each performed in triplicate samples (n 5 9; *P < 0.05 compared with control cells). D: Time-dependent changes in pGSK3b Ser9 levels in cells incubated without or with (5 lg/ml) human rPLTP for 6, 24, and 48 hr. E: pGSK3b Ser9 levels in cells incubated without or with (5 lg/ml) rPLTP for 48 hr under serum-free conditions and in the presence of serum. Antibodies against GSK3b (total and phosphorylated) were used at 1:800; anti-actin antibody was used at 1:12,000. Hampel et al., 2004; Hoe et al., 2006) . Phosphorylated Dab1 activates the PI3K pathway, leading to reduced activity of GSK3b and reduced tau phosphorylation (references given above). The other major pathway involves binding of a ligand to one of the receptor tyrosine kinases (RTK), which leads to activation of the PI3K pathway and reduced GSK3b activity (Castri et al., 2007; Biswas et al., 2008) . Because PLTP functions as a molecular partner of apoE, we tested the possibility that PLTP reduces tau phosphorylation through the same pathway utilized by apoE, by activation of Dab1.
We incubated HCN2 cells with PLTP and, after incubation, evaluated levels of total Dab1 and Dab1 phosphorylated at tyrosine 232 and 220, pDab1 Tyr232 and pDab1 Tyr220 . Western blot analyses have shown that PLTP significantly reduced levels of total Dab1 protein levels in neuronal cells (Fig. 4A,B) . PLTP also reduced DAB1 mRNA expression in human neuroblastoma cells, SK-N-SH, by 26% at 10 lg/ml rPLTP (P < 0.02 compared with control).
Furthermore, we have shown that PLTP significantly reduced levels of pDab1 Tyr232 (by 41%, 58%, and 60% at 2, 5, and 10 lg/ml rPLTP, respectively; Fig.  4C ,E), a site known to be phosphorylated by Fyn (Howell et al., 1999a) . The PLTP-mediated reduction in levels of pDab1 Tyr232 was present at 6 hr and developed further at 24 and 48 hr (Fig. 4D) . Addition or removal of serum did not affect PLTP-mediated reduction of pDab1 Tyr232 (Fig. 4F) . Similar results were obtained for pDab1 Tyr220 (data not shown), which is also regulated by Fyn.
Incubation of HCN2 cells with PLTP also reduced Dab1 phosphorylation at serine 491, pDab1 Ser491 (Fig.  4G) , a residue phosphorylated by cyclin-dependent kinase 5 (Cdk5), both in vivo and in vitro, in a process that previous studies have shown to be independent of Reelin (Keshvara et al., 2002; Ohshima et al., 2006) . However, because of the similar extent of the PLTP effect on levels of total Dab1, it is not clear whether the reduction in pDab1 Ser491 is due to the PLTP-induced reduction in Cdk5-dependent Dab1 phosphorylation or to the reduction in total Dab1.
PLTP and Akt/PKB
To evaluate the effect of PLTP on Akt/PKB activation, we incubated HCN2 cells with or without PLTP for 10 and 30 min. As expected, incubation with PLTP increased levels of pAkt Thr308 (Fig. 5B ) and pAkt Ser473 (Fig. 5C) , without increasing the levels of total Akt (Fig. 5A) . PLTP-mediated increase of phospho-Akt was prolonged and was still present at 6 hr (data not shown).
Additionally, we inhibited tyrosine kinase activity of two receptor tyrosine kinases, insulin receptor (IR) and insulin-like growth factor 1 (IGF-1) receptor (IGFR), using the chemical inhibitor HNMPA(AM) 3 . Inhibition with 50 lM of HNMPA(AM) 3 , which has been shown to affect only IR, but not IGFR (Diaz et al., 2007) , had a limited effect on the PLTP-mediated increase in levels of pAkt Thr308 and pAkt Ser473 . However, inhibition with 100 lM of HNMPA(AM) 3 , which inhibits tyrosine kinase activity of both IR and IGFR (Diaz et al., 2007) , markedly inhibited PLTP-mediated effect on pAkt Thr308 (Fig. 5B ) and pAkt Ser473 (Fig. 5C ). Our data indicate that PLTP activates Akt at both activation sites and that this effect is dependent on the receptor tyrosine kinase activity of IR/IGFR. DISCUSSION PLTP is an important lipid transfer protein present in the brain, expressed and secreted by neurons and glia (Vuletic et al., 2003) . PLTP levels are significantly higher in brain tissue of early-to midstage AD patients, with subsequent significant decrease in patients with a severe neuronal loss (Vuletic et al., 2003) . Both our immunohistochemical and in vitro studies have shown that PLTP is highly expressed in neurons and that neuronal PLTP levels are significantly higher in neurons of AD patients compared with controls (Vuletic et al., 2003; and unpublished data) . However, the potential physiological effects of this significant intraneuronal increase of PLTP as well as the increase in PLTP levels in the brain tissue of AD patients are not known. Fig. 3 . Inhibition of phosphatidylinositol-3 kinase (PI3K) reverses PLTP-induced changes on phosphorylation of GSK3b and tau. Cells were incubated without or with (5 lg/ml) human rPLTP for 48 hr under serum-free conditions, in the presence or absence of the PI3K inhibitor LY294002 (50 lM). A: pGSK3b Ser9 . B: pTau Thr231 . Antibodies against tau and GSK3b were used at 1:800; anti-actin antibody was used at 1:12,000.
Here we provide evidence that PLTP significantly reduces levels of tau phosphorylated at residues phosphorylated by GSK3b and increases levels of the inactive form of GSK3b in vitro. Furthermore, our findings indicate that the increase in pGSK3b Ser9 levels does not fully explain the reduction in tau phosphorylation induced by PLTP, suggesting that PLTP activates an additional pathway. Previous studies have shown that regulation of pTau Thr231 is affected by activities of GSK3b, Cdk5 and protein phosphatase 2A (PP2A; Wang et al., 2007) . GSK3 plays an important role in the pathogenesis of AD (Hooper et al., 2008) . Therefore, our finding that PLTP increases levels of pGSK3b Ser9 is relevant for AD, insofar as GSK3b inhibitors are considered to be among the most promising therapeutic approaches for the treatment of AD (Martinez and Perez, 2008) .
Phosphorylation of GSK3b at serine 9 and consequential inactivation of this kinase involve the PI3K pathway (Krasilnikov, 2000) , the downstream effector of Fig. 4 . PLTP reduces levels of total Disabled-1 (Dab1) and levels of Dab1 phosphorylated at tyrosine 232 and serine 491 in HCN2 cells. Western blot analyses of cytoplasmic proteins (30 lg) isolated from the HCN2 cells incubated without or with (2, 5, or 10 lg/ml) human rPLTP for up to 48 hr. A: Total Dab1. B: Time-dependent changes in levels of total Dab1. C: Levels of pDab1 Tyr232 . D: Timedependent changes in pDab1 Tyr232 levels. E: PLTP effect on levels of pDab1 Tyr232 ; results of three separate experiments performed in triple replicates (n 5 9; *P < 0.05 compared with control cells). F: pDab1 Tyr232 levels in cells incubated without or with serum. G: Levels of pDab1 Ser491 in cells incubated for 48 hr in serum-free media. Antibodies against Dab1 (total and phosphorylated) were used at 1:800; anti-actin antibody was used at 1:12,000.
the Reelin/pDab1-mediated regulation of GSK3b activity (Beffert et al., 2002) . In our studies, inhibition of the PI3K pathway reversed the PLTP-induced phosphorylation of GSK3b and partially reversed PLTP-induced reduction of phosphorylation of tau. However, contrary to our expectations, PLTP reduced protein levels of Dab1 as well as levels of Dab1 phosphorylated at tyrosine residues. These findings suggest that PLTP-mediated reduction in tau phosphorylation is not executed through the Dab1-dependent mechanism, because previous studies have shown that reduction in Dab1 tyrosine phosphorylation is associated with an increase in GSK3b-dependent tau phosphorylation (Hiesberger et al., 1999; Brich et al., 2003; Hoe et al., 2006) . Although PLTP-modulated reduction of tau phosphorylation seems to be independent of Dab1, our findings strongly suggest that PLTP has a significant effect on Dab1 levels and function in human neurons.
Previous studies have shown that activation of the PI3K pathway is also regulated by ligand binding to the RTK. It is, therefore, possible that PLTP modulates the PI3K pathway through this mechanism. Indeed, in our experiments, we have shown that inhibition of receptor tyrosine kinase activity of the IR/IGFR blocks PLTP- Fig. 5 . PLTP increases levels of active Akt/PKB, and this effect is inhibited by HNMPA(AM) 3 , the insulin receptor and IGF-1 receptor tyrosine kinase activity inhibitor. Western blot analyses of cytoplasmic proteins (30 lg) isolated from the HCN2 cells. The cells were incubated with HNMPA(AM) 3 or vehicle (DMSO) for 2 hr prior to addition of PLTP. The cells were then exposed to PLTP for 10 and 30 min. A: Total Akt. B: pAkt Thr308 . C: pAkt Ser473 . Antibodies against Akt (total and phosphorylated) were used at 1:1,000; anti-actin antibody was used at 1:12,000. mediated activation of Akt/PKB, suggesting that PLTP effect is dependent on IR/IGFR tyrosine kinase activity.
Additionally, the activation of PI3K is regulated by phosphatidylinositol (PI), and in vivo and in vitro studies have shown that the presence of PLTP is required for transfer of PI, with a complete abolition of PI transfer in PLTP-deficient mice (Jiang et al., 1999) . It is, therefore, reasonable to propose that PLTP might modulate the PI3K pathway also through regulation of substrate delivery to PI3K.
The findings presented here also have broader implications. Dab1, PI3K, GSK3b, and Cdk5 are important for numerous other processes, such as inflammation, apoptosis, and the cell cycle, and alterations in their activity have been reported as important factors in development of many diseases, including cancer. Therefore, further investigation of the relationship between PLTP and these molecules is likely to provide new insights into the physiological regulation of these highly relevant intracellular processes associated with numerous human diseases.
In summary, our study suggests that PLTP plays an important role in modulation of tau phosphorylation in neurons. Furthermore, our findings strongly suggest that the PLTP-induced inactivation of GSK3b and modulation of Dab1 in neurons are achieved through separate, independent mechanisms and pathways. We postulate, based on our findings, that the increased levels of PLTP observed in the brain tissue of patients with AD would likely have beneficial effects by reducing the burden of tau phosphorylation and the formation of neurofibrillary tangles in neurons.
